Biotech Startups

Higher Steaks uses cell culture techniques to grow meat products from animal cell samples without traditional animal farming. The company serves food producers and consumers seeking cultivated meat alternatives.

1 investor

Highfield Diagnostics develops point-of-care diagnostic sensors using laser-based technologies on paper substrates, targeting detection of diseases like tuberculosis and leishmaniasis in resource-limited settings. The company applies laser engineering and microfluidics expertise to create affordable, low-cost diagnostic tests.

1 investor

HIGHR produces an organic glossing lip oil that blends natural oils and butters as alternatives to silicone and petroleum-based ingredients, packaged in recyclable glass and made in the USA. The product line serves consumers seeking natural beauty products with sustainable packaging.

1 investor

HighTechXL is an organization that supports deep-tech venture creation by sourcing and evaluating emerging technologies from research institutions and tech companies, then matching them with co-founders to establish new ventures. The organization focuses on deep-tech innovations that address significant societal challenges.

1 investor

HighTide Therapeutics is a biopharmaceutical company developing multifunctional therapies targeting cardiovascular-kidney-metabolic diseases. The company has a globally integrated pipeline with lead asset HTD1801 designated as a Fast Track and Orphan Drug candidate by the FDA.

1 investor

Hill Research builds multi-agent AI and automation for clinical trial data workflows, covering statistical programming, dataset generation, and regulatory submission documents from protocol design to FDA submission. It serves global pharmaceutical companies with biostatistics software and functional service provider solutions.

1 investor

HISHOH Biopharma develops and commercializes pharmaceutical compounds using proprietary drug discovery technology, supported by a team with extensive R&D experience from Japanese pharmaceutical companies and supported by venture capital investors.

1 investor

Histide is a biotech intellectual property platform company developing a class of non-mutagenic extracellular therapeutic agents called Cell Recoding Molecules (CRM), which act on the cell's microenvironment to redirect cell fate for tissue regeneration and disease treatment. Its Recoding Therapeutics platform targets applications across pharmaceuticals, medical devices, and medical cosmetics, with a pipeline spanning five strategic therapeutic areas.

1 investor

Histocell is a biopharmaceutical company focused on regenerative medicine that develops and manufactures cell therapy products, biologics, and medical and dermocosmetic products. Its work spans two units: advanced therapy medicines and medical/dermocosmetic products.

1 investor

HLB PEP manufactures and supplies peptide pharmaceutical ingredients, producing generic peptides and custom-synthesized peptides at a GMP facility. It also runs catalog research peptides (hormones, neuropeptides, antibiotic peptides, neurotoxins) and pursues new drug candidate discovery for licensing and commercialization.

1 investor

HLN-Genetik is a privately operated human genetics laboratory in Vienna offering reproductive genetics (preimplantation and polar body diagnostics, carrier and miscarriage testing) and human genetics analyses such as single-gene, panel, and exome testing. It works as a referral laboratory for Austrian and international physicians and IVF clinics.

1 investor

Hofseth BioCare develops products derived from fish, using patented processes and R&D programs including research on asthma, COVID-19, and gastrointestinal health. The company operates in the marine bioingredients and nutraceuticals space with an emphasis on ESG.

1 investor

HOIST is an Osaka University-derived biotech venture developing anti-cancer drugs, focusing on novel modalities and mechanisms of action for cancers that lack sufficient treatments. It also provides drug discovery support using PDC/PDX approaches.

1 investor

Holistaco develops food ingredient solutions including sweetening products and antimicrobial nano-silver compounds. The company serves health-conscious consumers and food manufacturers seeking reduced-sugar and antimicrobial alternatives.

1 investor

Holobiome discovers and develops therapies and next-generation probiotics derived from the human gut microbiome, aiming to address whole-body health challenges. The company applies microbiome science to create first-in-class treatments and targeted health solutions.

1 investor

Home Biosciences was a venture builder in Continental Europe dedicated to creating and scaling biotech companies through an asset-centric, hub-and-spoke model, working with academics and scientists on drug discovery and molecular profiling projects. It co-founded companies including One Biosciences, Sequantrix, and Apikal Therapeutics before ending day-to-day operations in January 2025 and moving to non-operating mode.

1 investor

HOOKIPA Pharma was a clinical-stage biopharmaceutical company developing immunotherapies based on its proprietary arenavirus platform to target T cells against cancer and infectious diseases like HBV, HIV, and HPV.

1 investor

Amgen is a biopharmaceutical company that develops and manufactures biologic medicines using living cells to treat serious illnesses with limited existing treatment options.

1 investor

Houdini Bio develops a DNA design platform using synthetic biology and machine learning to improve genetic medicines. The platform redesigns therapeutic DNA to escape cellular silencing pathways, enabling greater durability, safety, and cost-effectiveness for genetic medicine treatments.

1 investor

HTBA manufactures flavonoids, vitamin B12, and active pharmaceutical ingredients (APIs) for international customers from facilities in Spain and the United States. The company operates manufacturing plants and applications labs in Barcelona and Murcia (Spain), with a North American headquarters and lab in Cincinnati, Ohio.

1 investor

Thomson manufactures laboratory consumables including filter vials, shake flasks, well plates, and chromatography columns for pharmaceutical, biotech, environmental, toxicology, and contract manufacturing sectors.

1 investor

Knoxville-based company funded via the INCITE Fund

1 investor

Hudson River BioTech pioneers the application of Protoplast-CRISPR technology for plant breeding, developing more resilient crops for agricultural producers and consumer packaged goods companies. The company offers a proprietary BioMaas platform and develops optimized agricultural products including fruits and vegetables.

1 investor

HuidaGene develops CRISPR and RNA-guided gene editing technologies for therapeutic applications in neurology, ophthalmology, otology, myology, and hepatology. The company employs the PRECISE platform for rational engineering of nucleases to advance targeted gene therapies.

1 investor